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Abstract
Background: Smoking is a risk factor for various lung diseases in which BAL may be used as a part of a clinical investigation.
Interpretation of BAL fluid cellularity is however difficult due to high variability, in particular among smokers. In this study
we aimed to evaluate the effect of smoking on BAL cellular components in asymptomatic smokers. The effects of smoking
cessation, age and gender were also investigated in groups of smokers and exsmokers.
Methods: We performed a retrospective review of BAL findings, to our knowledge the largest single center investigation, in
our department from 1999 to 2009. One hundred thirty two current smokers (48 males and 84 females) and 44 ex-smokers
(16 males and 28 females) were included. A group of 295 (132 males and 163 females) never-smokers served as reference.
Result: The median [5–95 pctl] total number of cells and cell concentration in current smokers were 63.4 [28.6–132.1]610
6
and 382.1 [189.7–864.3]610
6/L respectively and correlated positively to the cumulative smoking history. Macrophages were
the predominant cell type (96.7% [90.4–99.0]) followed by lymphocytes (2% [0.8–7.7]) and neutrophils (0.6% [0–2.9]). The
concentration of all inflammatory cells was increased in smokers compared to never smokers and ex-smokers. BAL fluid
recovery was negatively correlated with age (p,0.001). Smoking men had a lower BAL fluid recovery than smoking women.
Conclusion: Smoking has a profound effect on BAL fluid cellularity, which is dependent on smoking history. Our results
performed on a large group of current smokers and ex-smokers in a well standardized way, can contribute to better
interpretation of BAL fluid cellularity in clinical context.
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Introduction
Bronchoalveolar lavage is a noninvasive method which allows
sampling of cells and soluble components from the lower
respiratory tract [1,2,3,4,5]. The method was introduced in the
1970s [6] and has gained acceptance as a research but also as a
diagnostic tool. The differential cell count in BAL fluid may
provide information supporting the diagnosis of diffuse interstitial
lung diseases. For instance, in idiopathic pulmonary fibrosis
neutrophils and eosinophils are increased, and in hypersensitivity
pneumonitis and sarcoidosis a lymphocytic alveolitis is seen
[7,8,9,10]. Cellular analyses of BAL fluid in combination with
clinical and chest radiographic findings may thus reduce the need
for more invasive biopsy procedures. Furthermore, in a few rare
diseases such as pulmonary Langerhans cell histiocytosis with
increased proportion of CD1a+ cells and idiopathic pulmonary
hemosiderosis with hemosiderin laden macrophages, BAL can
confirm the diagnosis [9,11]. Since BAL samples the distal part of
the lung, i.e. the alveoli and the small airways, and the epithelial
lining fluid is directly exposed to the environment, the exposure
situation and the local milieu have a substantial impact both on the
cellular and non-cellular components of the recovered fluid
[9,12,13,14,15,16]. Cigarette smoking is a well-defined common
pollutant, which influences both cellular and soluble components
of BAL fluid. For example, smoking subjects have a significant
elevated number of cells in the lower respiratory tract, mainly due
to an increased number of alveolar macrophages [8,14,17,18]
Cigarette smoking is also a risk factor for various lung diseases
[19,20,21,22] such as chronic obstructive pulmonary disease
(COPD), usual interstitial pneumonia (UIP), desquamative inter-
stitial pneumonia (DIP), respiratory bronchiolitis associated
interstitial lung disease (RB-ILD) and pulmonary Langerhans cell
histiocytosis (PLCH). Since these patients may undergo BAL as a
part of a clinical investigation [19,23], it is important to distinguish
inflammatory changes due to cigarette smoking per se from changes
due to the disease. The establishment of a standardized reference
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better interpretation and utility of this important diagnostic tool in
a clinical framework.
In this retrospective analysis we therefore investigated effects of
cigarette smoking on BAL fluid cellular findings in a large number
of healthy asymptomatic smokers and ex-smokers with the aim of
establishing reference values to be used in a clinical setting.
Specifically, we made an effort to elucidate the effects of
accumulated smoking history, age and gender on BAL fluid cell
contents. In addition, the long term effect of smoking cessation was
addressed.
Materials and Methods
Study design
We performed a retrospective analysis of BAL investigations
done at our department on subjects who had participated as
healthy volunteers in various research projects from 1990 to 2009.
All individuals were recruited by word of mouth or by
advertisement in local newspapers and were reimbursed for their
participation.
Ethics statement
This was a retrospective study and all the subjects had
previously participated as control groups in different studies,
conducted during 1990–2009. All these individual studies had
previously been approved by the Regional Ethical Review Board
in Stockholm, Sweden. Informed consent has been obtained
previous from all participants in each study. In the 90s only verbal
consent was required. In studies performed in the 2000s also
written consent has been obtained. In the present retrospective
study, all data were analyzed anonymously.
Subjects
We identified 132 subjects (48 males and 84 females) who were
current smokers at the time of bronchoscopy. Their smoking
history was recorded and is presented as pack-years (Table 1).
Current smokers older than forty years of age underwent a
dynamic spirometry (Vitalograph MDI-Compact; Buckingham
Hamburg, Germany), and they were included only if they had a
FEV1/FVC.0.7 and a FEV1.80% of predicted normal values
according to the European Community for Steel and Coal (ECSC)
[24]. Subjects with allergy, asthma or any clinical history of other
respiratory diseases were excluded. All subjects underwent a
posterior-anterior and lateral chest X-ray and a routine medical
examination, and all findings had to be within the normal range.
No clinical signs of upper or lower respiratory infection for at least
four weeks before investigation were allowed. We also included 44
ex-smokers (16 males 28 females) who had quit smoking at least
ten months prior to the investigation and fulfilled the same
inclusion and exclusion criteria as the current smokers. As a
nonsmoking reference group we used a cohort of 295 never
smokers (163 females and 132 males) who are described in detail
elsewhere (Olsen HH et al, submitted).
Bronchoscopy and BAL
The subjects were fasting for at least eight hours prior to the
procedure. Participants received pre-medication with morphine-
hyoscin or pethidine and atropine intramuscularly 45 minutes
before the investigation. Bronchoscopy and BAL was then
performed in the morning by experienced bronchoscopists assisted
by research nurses according to a standardized protocol on an
outpatient basis. All bronchoscopies were performed in our
department. Briefly, after topical anesthesia with lignocaine, the
bronchoscope (Olympus F Type P 30 or equivalent instruments;
Olympus Optical Co. Ltd, Tokyo, Japan) was inserted nasally with
the subject in supine position. The tip of the bronchoscope was
wedged in a subsegmental bronchus of the middle lob, or in a few
cases in the lingula lobe. Five aliquots of 50 mL phosphate-
buffered saline solution at 37uC were instilled. After each
instillation, the fluid was gently suctioned back with a negative
pressure of 240 to 250 mm Hg. If the recovery appeared to be
poor, the suction pressure was occasionally adjusted to 210 to
220 mmHg. Dwell time was kept to a minimum as recommended
by the European Respiratory Society (ERS) task force [25]. The
five BAL fluid aliquots were pooled and collected in a silicone
treated plastic bottle which was kept on ice and immediately
transported to the laboratory.
Preparation of BAL fluid
All BAL fluids were prepared and analyzed at the Lung
Research Laboratory at the Department of Medicine at
Karolinska Institutet by experienced laboratory technicians. The
BAL fluid was filtered through a Dacrone layer (Type AP32;
Millipore, Cork, Ireland). The volume of the recovered fluid was
measured and the recovery percentage was calculated. Cell pellet
was prepared by centrifugation at 4006g for ten minutes at 4uC,
and was then re-suspended in RPMI 1640 medium (Sigma, St.
Louis, USA). Cell count and cell viability were assessed after
staining with trypan blue, using a Bu ¨rker Chamber (Marienfeld,
Germany). Cytocentrifugation (Cytospin 2; Shandon LTD,
Runcorn, UK) at 226g for three minutes was employed for cell
differential count. After staining with May-Gru ¨nwald Giemsa 500
cells were counted. Mast cells were stained with toluidine blue, and
the number of cells within 10 visual fields (166magnifications) was
scored and reported as absolute number of these cells. Findings
were reported as both total cell count and cell concentration, and
differential cell count as concentration and percentage of the total
cell number.
Statistical analysis
Descriptive statistics were used to define the reference values
defined as the 5
th and 95
th percentiles for current smoking
subjects. Comparisons between groups were performed by analysis
of variance, using the Satterthwaite approximation in case of
unequal variance between the groups. In order to examine the
influence of smoking history (pack years) and age on BAL fluid
components we employed a stepwise regression analysis using
Pearson correlation coefficient. Since the study was regarded as
exploratory, no corrections due to multiple analyses were
performed in order to avoid false negative conclusions and a p
value,0.05 was considered significant. However, p-values above
0.005 should be interpreted with caution.
Results
Recovery, total cell count and differential cell count in
current smokers
Results from the current smoking group are presented in
Table 2. Recovery of instilled fluid ranged from 34% to 82%, and
the median viability was 91% (range 70% to 100%). The median
total number of cells and cell concentration were 63.4610
6 and
382.1610
6/L respectively. The inter-individual variability was
large ranging from 11.5610
6 to 177.8610
6 for total cell count and
67.5610
6/L to 1280610
6/L for cell concentration respectively,
and the variability showed a tendency to be more pronounced at
higher ages. The majority of cells were alveolar macrophages
(median 96.7%; range 73.2–99.6%) followed by lymphocytes
Effects of Smoking on BAL Fluid Cellularity
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e34232(median 2%; range 0.2–26%) and neutrophils (median 0.6%;
range 0–6%). Basophils, eosinophils and mast cells were
represented scarcely. As for total cell number and cell concentra-
tion, the inter-individual variability was large for the differential
counts, in particular with regard to the concentration of
macrophages which varied by a factor 20 between minimum
and maximum (64.1610
6/L and 1274610
6/L respectively).
Correlations with smoking history and age
Both return volume and percentage of recovered fluid showed a
statistically significant correlation with age (p,0.001 for both) but
not with smoking history (Table 3 and Figure 1). Cell viability was
negatively correlated with age (p,0.01) but no influence could be
seen from smoking history (Figure 2). Cell concentration was
significantly (p,0.001) correlated with smoking history but not
with age (Table 3, Figure 3, Figure 4 and Figure 5). As for total cell
number and cell concentration, there was a statistically significant
(p,0.001) correlation between macrophage concentration and
cumulative smoking history, but there was no correlation with age.
The percentage of eosinophils showed a statistically significant
correlation (p,0.05) with age but not with smoking history.
Comparison between smokers, ex-smokers and never
smokers
Results from comparison of data from smokers, ex-smokers and
never smokers are presented in Table 4. Cell count in current
smokers, exsmokers and never smokers are shown graphically in
Figure 6 (cell concentrations) and in Figure 7 (percentage of cells).
Both the BAL return volume and recovery were significantly lower
in smokers compared to never smokers and ex-smokers. Mean cell
viability was more than 90% in all three groups but was lower in
smokers. Total cell number and cell concentration showed almost
a four-fold increase in current smokers compared to the other two
groups. This was mainly due to an increased concentration of
alveolar macrophages, which was elevated by a factor five in
smokers compared to both never smokers and ex-smokers. The
concentration of lymphocytes was slightly higher in current
smokers compared to the other groups, but the difference was
not statistically significant. Measured as proportion of total cells,
the percentage of lymphocytes was almost three times higher in
never smokers compared to smokers and ex-smokers. The
concentration of neutrophils was increased in current smokers
and reached statistical significance compared to never smokers
Table 1. Characteristics of the study subjects.*
Current Smokers(N=132) Ex-Smokers (N=44) Never Smokers (N=292)
Age 39.3613.9 (20–66) 38.668.0 (26–54) 31.5611.7 (18–65)
b,c
Males/females 48/84 16/28 132/163
Pack-years 20.8615.1(2–84)
a 5.366.7(0.2–35) N.A.
Time since smoking cessation (months) N.A. 117.6677.3 (10–336) N.A.
*Values are expressed as mean6SD and range within brackets.
ap,0.0001 ‘‘Current Smokers’’ vs. ‘‘Ex-smokers’’.
bp,0.0001 ‘‘Current Smokers’’ vs. ‘‘Never Smokers’’.
cp,0.0001 ‘‘Ex-smokers’’ vs. ‘‘Never Smokers’’.
N.A. not applicable.
doi:10.1371/journal.pone.0034232.t001
Table 2. Descriptive statistics of BAL findings in current smoking subjects.
Variable N Minimum Median Maximum 5
th Pctl 95
th Pctl
Return volume (mL) 128 86 164 204 119 188
Recovery (%) 128 34 66 82 48 75
Viability (%) 132 70 91 100 80 99
Total cell number (10
6) 128 11.5 63.4 177.8 28.6 132.1
Cell concentration (10
6/L) 128 67.5 382.1 1280 189.7 864.3
Macrophages (%) 132 73.2 96.7 99.6 90.4 99.0
Macrophages (10
6/L) 128 64.1 356.8 1 274.9 172.2 842.2
Lymphocytes (%) 132 0.2 2 26 0.8 7.7
Lymphocytes (10
6/L) 128 1.1 7.8 65.7 2.2 34.8
Neutrophils (%) 131 0 0.6 6 0 2.9
Neutrophils (10
6/L) 127 0 2.5 30.4 0 13.2
Eosinophils (%) 132 0 0 3.6 0 1.4
Eosinophils (10
6/L) 128 0 0 14.6 0 5.5
Basophils (%) 132 0 0 2 0 0.1
Basophils (10
6/L) 128 0 0 4.4 0 0. 5
Mast cells (per 10 visual fields) 65 0 2 13 0 8.8
doi:10.1371/journal.pone.0034232.t002
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but the concentration was significantly higher in smokers than in
never smokers and ex-smokers.
Gender differences in BAL fluid cellularity
Data from males and females separately are presented in
Table 5. The smoking males were older than the smoking females
(p,0.05) and had a higher cumulative cigarette consumption
(p,0.05). Among smokers, both the recovered volume and the
percentage of recovery were significantly lower in males compared
to females. A step wise regression of pack years and age with
recovery revealed that fluid recovery still was significant lower in
the male smokers compared to the female smokers. In the ex-
smoker group there were no significant differences between men
and women.
Discussion
In the present study, we retrospectively analyzed the effects of
cigarette smoking on cellular components in BAL fluid in a large
number of asymptomatic smoking volunteers. There was a
Figure 1. Relation between percentage of recovered fluid in BAL and age from current smokers and ex-smokers.
doi:10.1371/journal.pone.0034232.g001
Figure 2. Relation between cell viability in BAL fluid and age from current smokers and ex-smokers.
doi:10.1371/journal.pone.0034232.g002
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The total cell count and cell concentration were positively
correlated to cumulative smoking history with considerable intra-
individual variability. Compared to healthy never smokers, the cell
concentration were four-fold increased with an increased concen-
tration of all inflammatory cells, in particular macrophages.
The present study is, to our knowledge, the largest single centre
investigation attempting to elucidate the effects of smoking on
BAL fluid cellularity. Previous studies [4,5,18,26,27] have been
performed in rather small groups and the instilled volume fluid has
varied between 100–300 ml Nevertheless, it is reported a mean
total cell count for asymptomatic smokers between 14.4–
82.7610
6, a percentage of neutrophils of 0–8%, and a percentage
of lymphocytes of 3–8%, which are in the same range as our
results.
We performed our lavages by instilling 250 mL in the middle
lobe. There are reports [4,12,18,28] that larger lavage volumes
contains cells representing alveoli and distal airways while smaller
Figure 3. Total cell concentration (10
6/L) in relation to age and smoking history in BAL fluid from current smokers, in three
different groups according to age and smoking history expressed as pack-years (PY).
doi:10.1371/journal.pone.0034232.g003
Table 3. Step wise regression of pack-years and age with BAL findings in current smoking subjects.
Model Intecept Pack-years Age
Variable p Estim. (SE) p Estim. (SE) p Estim.(SE) p
Return volume (mL) ,.001 187.8 (5.6) ,.001 … n.s. 20.7 (0.1) ,.001
Recovery (%) ,.001 75.1 (2.2) ,.001 … n.s. 20.3 (0.1) ,.001
Viability (%) ,.01 85.8 (1.5) ,.001 … n.s. 0.1 (0.0) ,.01
Total cell number (10
6) ,.01 55.5 (5.2) ,.001 0.6 (0.2) ,.01 … n.s.
Cell concentration (10
6/L) ,.001 313.3 (32.8) ,.001 5.8 (1.3) ,.001 … n.s.
Macrophages (%) n.s. … n.s. … n.s. … n.s.
Macrophages (10
6/L) ,.001 297.7 (31.8) ,.001 5.7 (1.2) ,.001 … n.s.
Lymphocytes (%) n.s. … n.s. n.s. … n.s.
Lymphocytes (10
6/L) n.s. … n.s. … n.s. … n.s.
Neutrophils (%) n.s. … n.s. … n.s. … n.s.
Neutrophils (10
6/L) n.s. … n.s. … n.s. … n.s.
Eosinophils (%) ,.05 .628 (.145) ,.001 … n.s. .001 (.003) ,.05
Eosinophils (10
6/L) n.s. … n.s. … n.s. … n.s.
Basophils (%) n.s. … n.s. … n.s. … n.s.
Basophils (10
6/L) n.s. … n.s. … n.s. … n.s.
Mast cells (per 10 visual fields) n.s. … n.s. … n.s. … n.s.
doi:10.1371/journal.pone.0034232.t003
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airways. Larger volume also increases the possibility to harvest
more viable cells. However, our own experience is that volumes of
300 mL or more increases the risk of lavage-related fever. In our
department, with more than three decades of experience of BAL
investigations, we have standardized the method by instilling
250 mL with no significant adverse effect. However, the optimal
lavage volume is not yet determined.
The most striking effect of cigarette smoking is an increased
number of cells, in particular macrophages [8,14,15,18,29,30,31]
Macrophages are the first line of defence against inhaled pollutants
including tobacco smoking. Macrophages obtained from smokers
have a changed morphology [32,33]. They have an altered
phenotype pattern and impaired function [30,34,35,36,37], they
show defect functions in killing bacteria [38] and have inhibitory
effects on lymphocytes and natural killer cells [39,40]. Fraig et al
[41] found sign of respiratory bronchiolitis with increased numbers
of pigmented macrophages in lung parenchyma in almost 100% of
asymptomatic smokers in a biopsy material, and the intensity of
inflammation was correlated to smoking history. A cigarette dose-
related inflammatory response with increased numbers of
Figure 5. Relation between cell concentration and age in BAL fluid from current smokers and ex-smokers.
doi:10.1371/journal.pone.0034232.g005
Figure 4. Relation between cell concentration (10
6/L) in BAL fluid and smoking history expressed in pack-years, from current
smokers.
doi:10.1371/journal.pone.0034232.g004
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reported by Kuchner et al [14].
We found a lower recovery with increasing age both in smokers,
and ex-smokers which have also been reported by other
investigators [18,42]. This can likely be explained by a reduced
compliance in the lung parenchyma with age since smoking results
in an accelerated aging process in the lungs and development of
emphysema [18,44]. In a previous paper, we demonstrated that
BAL fluid recovery correlates with measures of emphysema in
patients with COPD [43].
We found no differences in BAL fluid parameters between
never smokers and ex-smokers. Our data indicate therefore that a
normalization of BAL cells after smoking cessation in our ex-
smoking group had occurred. In the study by the BAL steering
committee [18] a moderate but statistically significant increase in
neutrophils was observed in ex-smokers compared to never-
smokers. However, the ex-smokers in that study had higher
cumulative smoking history than in our study, 14.5 versus 5.3 pack
years. An increased number of neutrophils in healthy ex-smokers
have also been reported by other investigators [45]. The
normalization process after smoking cessation is likely depending
Figure 6. Cell concentration (10
6/L) of the various inflammatory cells in BAL fluid in current- smokers (CS) and never-smokers (NS)
and ex-smokers (ES). Mean and standard deviation are given.
doi:10.1371/journal.pone.0034232.g006
Table 4. Bronchoalveolar lavage findings in current smoking, never-smoking and ex-smoking subjects.
Smokers Never-smokers Ex-smokers Model
Variable N Mean (SD) N Mean (SD) N Mean (SD) P
Return volume (mL) 128 158.4 (22.5) #1 266 179. (23.6) 41 171.7 (26.7) ,.0001
Recovery (%) 128 63.3 (9.0) #1 266 71.9 (9.4) 41 68.7 (10.7) ,.0001
Viability (%) 132 90.2 (6.0) # 292 91.7 (5.1) 42 91.6 (4.1) 0.0225
Total cell number (10
6) 128 68.4 (34.8) #1 266 16.3 (7.6) 40 18.1 (9.5) ,.0001
Cell concentration (10
6/L) 128 436.3 (227.2) #1 266 91.9 (41.7) 40 104.5 (48.1) ,.0001
Macrophages (%) 132 95.8 (3.3) #1 284 88.1 (8.2) 43 90.3 (5.5) ,.0001
Macrophages (10
6/L) 128 418.9 (220.4) #1 255 80.0 (34.4) 39 92.4 (42.4) ,.0001
Lymphocytes (%) 132 2.97 (3.07) #1 284 9.66 (7.7) 43 7.60 (4.99) ,.0001
Lymphocytes (10
6/L) 128 12.29 (12.31) 255 9.45 (14.7) 39 7.16 (5.36) 0.0528
Neutrophils (%) 131 0.98 (1.04) #1 284 1.85 (1.96) 43 1.76 (1.38) ,.0001
Neutrophils (10
6/L) 127 3.96 (4.67) #1 255 1.63 (2.00) 39 1.95 (1.79) ,.0001
Eosinophils (%) 132 0.29 (0.54) 283 0.29 (0.63) 43 0.28 (0.45) 0.9916
Eosinophils (10
6/L) 128 1.23 (2.71) #1 254 0.27 (0.60) 39 0.29 (0.52) ,.0001
Basophils (%) 132 0.03 (0.18) 284 0.02 (0.06) 43 0.03 (0.11) 0.8306
Basophil (10
6/L) 128 0.09 (0.48) # 255 0.02 (0.06) 39 0.03 (0.12) 0.0340
Mast cells (per 10 visual fields) 65 2.91 (2.98) 214 2.96 (4.79) 30 2.17 (2.02) 0.6314
#Significantly different vs. Never Smokers.
1Significantly different vs. Ex-Smokers.
doi:10.1371/journal.pone.0034232.t004
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cessation, duration and intensity of smoking [46,47]. The long-
time course for effects of smoking cessation on BAL cells has not
been fully investigated. In a previous investigation from our
department [15], we found a significant fall in total cell count one
month after smoking cessation, and the values reached normal
levels within six months. Rennard et al [48] investigated heavy
smokers who reduced cigarette consumption from 50 to 19
cigarettes per day. There was a significant reduction in both
neutrophils and macrophages but also in elastase level after two
months [48]. Our study is in consistency with reversibility of
smoking induced cellular changes in the lower respiratory tract in
Table 5. Comparison of bronchoalveolar lavage findings between current smoking, and ex-smoking subjects divided in men and
women.
Smokers Ex-smokers
Variable Females Males p Females Males p
Number 84 48 28 16
Pack years 18.5 (2–66) 25.4 (3–84) 0.0176* 6.4 (0.2–35) 3.3 (0.2–5) 0.16
Age years mean (range) 37 (20–65) 42 (21–66) 0.0479 38 (26–54) 40 (27–54) 0.27
Return volume (mL) 163.9 (86–204) 149.2 (94–188) 0.0004*** 174 (100–215) 168 (126–198) 0.46
Recovery (%) 65.6 (34–82) 59.7 (38–75) 0.0004*** 70 (40–86) 67.2 (50–79) 0.45
Viability (%) 90.0 (70–100) 90.6 (79–100) 0.5736 90.9 (84–100) 92.7 (85–97) 0.16
Total Cell Number (10
6) 68.4 (12–178) 68.3 (21–167) 0.9969 17.3 (7–61) 19 (7.0–37) 0.54
Cell concentration (10
6/L) 420.3 (67–1143) 463.0 (164–1280) 0.3217 98 (40–285) 115 (52–207) 0.27
Macrophages (%) 95.8 (73–99) 95.8 (89–100) 0.9966 90 (73–98) 91 (83–99) 0.42
Macrophages (10
6/L) 403.8 (64–1114) 444.1 (160–1275) 0.3364 88.2 (36–258) 99.3 (49–174) 0.41
Lymphocytes (%) 2.9 (0.5–26) 3.1 (0.5–26) 0.6867 8.1 (0.8–26) 6.7 (0.8–14) 0.37
Lymphocytes (10
6/L) 11.3 (2–66) 14.0 (1–49) 0.2286 6.8 (1.4–17.4) 7.4 (0.7–21) 0.78
Neutrophils (%) 0.99 (0–6) 0.96 (0–6) 0.9083 1.8 (0–6.0) 1.6 (0.2–5.2) 0.69
Neutrophils (10
6/L) 3.8 (0–30) 4.2 (0–24) 0.6078 2.0 (0–5.2) 1.9 (0.3–7.2) 0.94
Eosinophils (%) 033 (0–3.6) 0.23 (0–1.4) 0.2351 0.23 (0.0–1.4) 0.40 (0.0–1.4) 0.43
Eosinophils (10
6/L) 0.33 (0–3.6) 0.23 (0–1.4) 0.2351 0.20 (0.0–1.3) 0.43 (0.0–2.8) 0.28
Basophils (%) 1.4 (0–15) 0.99 (0–12) 0.3902 0.007 (0.0–0.2) 0.06 (0.0–0.7) 0.29
Basophil (10
6/L) 0.01 (0–0.2) 0.05 ( 0–2) 0.3007 0.0 (0.0–0.0) 0.07 (0.0–0.65) 0.18
Mast Cells (per 10 visual fields) 3.1 (0–13) 2.7 (0–8) 0.6397 1.5 (0.0–0.5) 3.2 (0.0–9.0 0.04
*P,0.05.
***p,0.001.
doi:10.1371/journal.pone.0034232.t005
Figure 7. Differential cell count expressed in (% of total cells) in current smokers (CS) and neversmokers (NS) and ex-smokers (ES).
Mean and standard deviation are given.
doi:10.1371/journal.pone.0034232.g007
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and chronic bronchitis, who show signs of a persistent lower
airway neutrophilic inflammation after smoking cessation
[49,50,51] which could indicate a pathogenetic role for neutro-
phils in COPD.
A number of interstitial lung diseases are associated with
tobacco smoking. These rare diseases are rather heterogeneous
and complex with widely diverse clinical presentation. Although
BAL findings alone cannot stand as diagnostic criteria in these
diseases, BAL may provide valuable additional information. An
increased cell concentration and a high number of pigmented
macrophages in BAL is a typical feature of DIP and RB-ILD
which have been exclusively reported in smokers [19,20,41]. In
our smoking group, we found considerable intra-individual
variability but increased cell concentrations, particularly regarding
alveolar macrophages. There may therefore be an overlap
between asymptomatic smokers and smokers with interstitial lung
diseases. Thus, other diagnostic tools such as surgical lung biopsy,
HRCT, physiological parameters and clinical picture have to be
considered in the diagnostic work-up.
Gender differences related to BAL fluid cellularity has been
investigated in few studies and there are no reports on any
differences in BAL fluid cell subset related to sex [18,26,52]. This
is in agreement with our findings. We observed, however, lower
recovery of BAL fluid in smoking men compared to smoking
women. This difference was still significant after correction for age
and smoking history. The reason for this difference is not quite
clear, but it may be explained, by the fact that males are more
prone to develop emphysema than females [53]. A negative
correlation between the extent of emphysema and BAL fluid
recovery has previously been shown [43].
In conclusion, we are convinced that data presented in the
present paper may contribute to better interpretation of BAL
findings in smoking individuals, as this is the largest material on
asymptomatic smokers with a well-defined smoking history.
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